ERBB2 and breast carcinoma: In addition, the combination of trastuzumab with checkpoint blockade is being considered for use in the treatment of HER2+ breast cancer as its administration has been shown to lead to improved therapeutic efficacy in an animal model with primary resistance to immunotherapy [109].